The STEP-HFpEF study was a program of two sister trials. The study that you’ll hear about today is in heart failure with preserved ejection fraction (HFpEF) and obesity patients without type 2 diabetes. Learn more about semaglutide with Dr. Mary Katherine Cheeley as she speaks with fellow ReachMD host, Dr. Javed Butler, President of Baylor Scott and White Research Institute in Dallas, Texas.